Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022)

Junchen Li; Jianfeng Zhang; Chenqi Guo; Peng Lin; Qian Shen; Haiyue Lin; Yu Zhang

doi:10.1016/j.heliyon.2023.e23542

Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022)

Heliyon. 2023 Dec 10;10(1):e23542. doi: 10.1016/j.heliyon.2023.e23542. eCollection 2024 Jan 15.

Authors

Junchen Li¹, Jianfeng Zhang¹, Chenqi Guo¹, Peng Lin¹, Qian Shen², Haiyue Lin³, Yu Zhang³

Affiliations

¹ Graduate school, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
² Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
³ Dermatology department, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.

Abstract

Background: It is now understood that T cells play a key role in the occurrence and development of psoriasis. Herein, a bibliometric analysis was conducted to summarize the content and trends of T cell-related research in psoriasis.

Methods: A bibliometric analysis was conducted on publications pertaining to T cells in psoriasis between 2003 and 2022 retrieved from the Web of Science Core Collection (WoSCC) database using tools such as CiteSpace, the Bibliometrix R package, and VOSviewer.

Results: The study included a total of 3595 articles authored by 14,188 individuals, including all coauthors in article bylines. The Laboratory for Investigative Dermatology at Rockefeller University, led by James G Krueger, has made significant contributions to this field through focusing on the pathogenesis of psoriasis and exploring the potential of using biological agents to treat psoriasis. Furthermore, targeted inhibitors have significantly impacted the treatment of psoriasis, with researchers focusing on small-molecule targeted drugs as a new area of research that could potentially replace biological agents.

Conclusions: Research has established the efficacy and long-term safety of targeted inhibition of T cell-related targets. Deucravacitinib, a psoriasis treatment drug targeting TYK2 as an allosteric inhibitor, has attracted significant attention and raised high expectations.

Keywords: Bibliometric analysis; Biological agents; Psoriasis; Small-molecule targeted drugs; T cells; Targeted inhibitors.